Displaying drugs 601 - 625 of 2785 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| Setmelanotide | 1117.32 C49H68N18O9S2 |  | Setmelanotide is indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies or Bardet-Biedl syndrome. | Centrally Acting Antiobesity Products |
| Tropisetron | 284.3529 C17H20N2O2 |  | A 5HT-3 receptor antagonist used as an antiemetic in the treatment of chemotherapy-induced nausea and vomiting. | Serotonin 5-HT3 Receptor Antagonists |
| Pacritinib | 472.589 C28H32N4O3 |  | A kinase inhibitor used for the treatment of primary and secondary myelofibrosis in adult patients with significantly reduced platelet counts. | Janus Kinase Inhibitor |
| Voclosporin | 1214.646 C63H111N11O12 |  | A calcineurin inhibitor for the treatment of lupus nephritis (LN) in patients diagnosed with systemic lupus erythematosus (SLE). | Calcineurin Inhibitors |
| Naldemedine | 570.646 C32H34N4O6 |  | An opioid antagonist used to to treat opioid-induced constipation. | Peripheral Opioid Receptor Antagonists |
| Selumetinib | 457.68 C17H15BrClFN4O3 |  | A MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). | Mitogen-activated protein kinase (MEK) inhibitors |
| Daprodustat | 393.44 C19H27N3O6 |  | A small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor used for the treatment of anemia in patients with chronic kidney disease. | Amino Acids / Amino Acids, Peptides, and Proteins / Antianemic Preparations / BCRP/ABCG2 Substrates / Blood and Blood Forming Organs / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor / Hypoxia-Inducible Factor-Proline Dioxygenases, antagonists & inhibitors / OAT1/SLC22A6 Substrates / OAT3/SLC22A8 Substrates / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / Pyrimidines / Pyrimidinones |
| Fruquintinib | 393.399 C21H19N3O5 |  | A VEGF receptor inhibitor used to treat metastatic colorectal cancer. | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors |
| Treosulfan | 278.29 C6H14O8S2 |  | Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood. | Alkanesulfonates |
| Triheptanoin | 428.61 C24H44O6 |  | Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders. | Various Alimentary Tract and Metabolism Products |
| Curcumin | 368.3799 C21H20O6 |  | No approved therapeutic indications. | Antineoplastic Agents / Catechols / Coloring Agents / Diarylheptanoids / Enzyme Inhibitors |
| Latanoprostene bunod | 507.624 C27H41NO8 |  | A prostaglandin analog used to reduce ocular hypertension or treat open-angle glaucoma. | Prostaglandins, Synthetic |
| Rebamipide | 370.79 C19H15ClN2O4 |  | A gastroprotective agent used in combination with other similar therapies (e.g. proton pump inhibitors) to treat gastritis and protect the gastric mucosa. | Anti-Ulcer Agents / Antioxidants / Enzyme Inhibitors |
| Tucatinib | 480.532 C26H24N8O2 |  | A kinase inhibitor used to treat certain types of unresectable/metastatic HER-2 positive breast cancer. | Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors |
| Tafamidis | 308.116 C14H7Cl2NO3 |  | A medication used to treat transthyretin-mediated amyloidosis. | Anti-Inflammatory Agents |
| Pitolisant | 295.85 C17H26ClNO |  | An antagonist and inverse agonist at the histamine H3 receptor that is used to treat narcolepsy in adults. | Drugs causing inadvertant photosensitivity / Receptors, Histamine H3 |
| Vinflunine | 816.944 C45H54F2N4O8 |  | A vinca alkaloid used to treat advanced or metastatic transitional cell carcinoma of the urothelial tract after a platinum containing treatment has failed. | Vinca Alkaloids |
| Amifampridine | 109.132 C5H7N3 |  | A voltage gated potassium channel blocker used to treat Lambert-Eaton myasthenic syndrome. | Potassium Channel Blockers |
| Artenimol | 284.352 C15H24O5 |  | For the treatment of uncomplicated Plasmodium falciparum infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with DB13941. | Artemisinin and derivatives |
| Delamanid | 534.492 C25H25F3N4O6 |  | An antibiotic used to treat multidrug resistant tuberculosis. | Antiinfectives for Systemic Use / Antimycobacterials / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Treatment of Tuberculosis / Imidazoles / Moderate Risk QTc-Prolonging Agents / Nitro Compounds / QTc Prolonging Agents |
| Nomegestrol | 328.452 C21H28O3 |  | Nomegestrol is an ingredient in the EMA-authorised product Zoely. | Pregnadien Derivatives / Progestogens and Estrogens, Sequential Preparations |
| Tocofersolan | C33H54O5(C2H4O)n |  | A derivative of alpha tocopherol used to treat vitamin E deficiencies. | Drug Carriers |
| Colestilan chloride | (C7H11N2O)n.Cl |  | Colestilan is an ingredient in the EMA-withdrawn product BindRen. | Drugs for Treatment of Hyperkalemia and Hyperphosphatemia |
| Isavuconazole | 437.47 C22H17F2N5OS |  | Indicated for patients 18 years of age and older for the treatment of invasive aspergillosis [FDA Label]. Indicated for patients 18 years of age and older for the treatment of... | Triazole and tetrazole derivatives / Triazole Derivatives |
| Opicapone | 413.17 C15H10Cl2N4O6 |  | A catechol-O-methyltransferase inhibitor used as an adjunct treatment for Parkinson's Disease in adults currently receiving levodopa and a dopa decarboxylase inhibitor. | COMT Inhibitors |
Displaying drugs 601 - 625 of 2785 in total